Short Access to 6-Substituted Pyrimidine Derivatives by the SRN1 Mechanism. Synthesis of 6-Substituted Uracils through a One-Pot Procedure
摘要:
The synthesis of 6-substituted 2,4-dimethoxypyrimidines with different nucleophiles was accomplished with good to excellent yields (50-95%) through S(RN)1 reactions, starting from commercially available 6-chloro-2,4-dimethoxypyrimidine (1). Hydrolysis of these derivatives gave access to 6-substituted uracils with good yields and short times by the use of microwave irradiation. The preparation of uracils from 1 without the isolation of 2,4-dimethoxypyrimidine derivatives affords a rapid access to these compounds in good yields and excellent purity by avoiding an unnecessary step of purification.
Described are RORγ modulators of the formula (I),
or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORγ activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORγ activity, for example, autoimmune and/or inflammatory disorders.
PYRROLIDINYL SULFONE DERIVATIVES AND THEIR USE AS ROR GAMMA MODULATORS
申请人:Bristol-Myers Squibb Company
公开号:EP3092229B1
公开(公告)日:2018-03-28
US9458171B2
申请人:——
公开号:US9458171B2
公开(公告)日:2016-10-04
[EN] PYRROLIDINYL SULFONE DERIVATIVES AND THEIR USE AS ROR GAMMA MODULATORS<br/>[FR] DÉRIVÉS DE PYRROLIDINYLE SULFONE ET LEUR UTILISATION EN TANT QUE MODULATEURS DE ROR GAMMA
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2015103509A1
公开(公告)日:2015-07-09
Described are RORγ modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORγ activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORγ activity, for example, autoimmune and/or inflammatory disorders.